Biomea Fusion announces oral presentation of icovamenib data at the WCIRDC, highlighting potential advancements in type 2 diabetes treatment.
Quiver AI Summary
Biomea Fusion, Inc., a clinical-stage company focused on diabetes and obesity, announced that its long-term follow-up data for icovamenib will be presented orally at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles from December 3-6, 2025. Interim CEO Mick Hitchcock expressed excitement over being one of six chosen for an oral presentation, highlighting icovamenib's potential as a new treatment for insulin-deficient type 2 diabetes, a group that currently has limited options. Icovamenib is described as a novel, investigational therapy aimed at restoring insulin-producing beta cells. Biomea is committed to developing innovative therapies for metabolic disorders that affect a significant portion of the global population.
Potential Positives
- Biomea Fusion has been selected for an oral presentation at a prestigious international congress, highlighting the significance of its long-term icovamenib data in the diabetes research community.
- The company’s investigational drug, icovamenib, is positioned as a potential novel treatment for a largely underserved population with insulin-deficient type 2 diabetes, indicating the emphasis on addressing significant unmet medical needs.
- Being one of only six oral presentations at the conference underscores heightened interest in icovamenib, suggesting positive momentum and credibility within the diabetes treatment landscape.
Potential Negatives
- While being selected for an oral presentation is a positive aspect, the announcement highlights that icovamenib is still an investigational therapy, which implies that its commercialization is uncertain and dependent on ongoing clinical studies.
- The press release emphasizes the lack of therapeutic options for insulin-deficient diabetes, which may suggest that there are significant unmet needs in the market that icovamenib aims to address, indicating potential challenges in the competitive landscape.
FAQ
What is the focus of Biomea Fusion's presentation at WCIRDC 2025?
Biomea Fusion will present long-term follow-up data on icovamenib for type 2 diabetes treatment.
When will the oral presentation take place?
The oral presentation is scheduled for December 5, 2025, from 6:15 pm to 7:45 pm PST.
What is icovamenib and its potential benefit?
Icovamenib is an investigational therapy aiming to restore insulin-producing beta cells in insulin-deficient type 2 diabetes patients.
Why is icovamenib significant for diabetes treatment?
Icovamenib could serve as the first non-chronic therapy for type 2 diabetes, addressing an underserved patient population.
How can I access the presentation materials?
Presentation materials will be available on Biomea Fusion's website following the congress.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BMEA Hedge Fund Activity
We have seen 36 institutional investors add shares of $BMEA stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC removed 2,401,703 shares (-62.6%) from their portfolio in Q3 2025, for an estimated $4,851,440
- BLUE OWL CAPITAL HOLDINGS LP removed 1,300,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,626,000
- RENAISSANCE TECHNOLOGIES LLC added 595,900 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,203,718
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 500,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,010,000
- MILLENNIUM MANAGEMENT LLC removed 455,956 shares (-97.9%) from their portfolio in Q3 2025, for an estimated $921,031
- WOODLINE PARTNERS LP removed 443,000 shares (-25.4%) from their portfolio in Q3 2025, for an estimated $894,860
- FMR LLC added 372,940 shares (+5.1%) to their portfolio in Q3 2025, for an estimated $753,338
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BMEA Analyst Ratings
Wall Street analysts have issued reports on $BMEA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 11/10/2025
- D. Boral Capital issued a "Buy" rating on 11/05/2025
- Jefferies issued a "Buy" rating on 08/28/2025
To track analyst ratings and price targets for $BMEA, check out Quiver Quantitative's $BMEA forecast page.
$BMEA Price Targets
Multiple analysts have issued price targets for $BMEA recently. We have seen 4 analysts offer price targets for $BMEA in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $6.0 on 11/10/2025
- Jason Kolbert from D. Boral Capital set a target price of $12.0 on 11/05/2025
- Roger Song from Jefferies set a target price of $5.0 on 08/28/2025
- George Farmer from Scotiabank set a target price of $10.0 on 08/06/2025
Full Release
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 2025. The Congress showcases cutting-edge developments from both emerging investigators and world-renowned leaders.
“We are delighted to present our Week 52 long-term follow up data at WCIRDC, a meeting renowned for showcasing exciting advances in diabetes and metabolic research,” said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. “Being one of only six oral presentations this year speaks to the interest in icovamenib as a potential paradigm shift in the treatment of type 2 diabetes. Insulin-deficient diabetes remains an underserved population with limited therapeutic options, and icovamenib is potentially a novel treatment option for these patients.”
Oral Presentation Abstract #0062
COVALENT-111: Durable Glycemic and C-Peptide Improvements with Icovamenib, a Menin Inhibitor Targeting β-Cell Restoration in Insulin-Deficient Type 2 Diabetes
Presentation Time
Oral Presentation: December 5, 2025, from 6:15 pm – 7:45 pm PST
Please find a link here to our website where the poster and presentations will be available.
About Icovamenib
Icovamenib is an investigational, orally bioavailable, potent, and selective covalent inhibitor of menin. The proposed mechanism of action for icovamenib in diabetes is selective and partial inhibition of menin, a regulator of beta cell quantity and function, thereby enabling the proliferation, preservation, and reactivation of a patient’s own healthy, functional, insulin-producing beta cells. As the first non-chronic therapy for T2D, icovamenib could become an important addition to the diabetes treatment landscape once it has successfully completed its ongoing clinical studies.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at www.biomeafusion.com and follow us on LinkedIn , X and Facebook .
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
[email protected]
